- $315.99m
- $1.24bn
- $0.89m
ProKidney Q3 loss widens on higher R&D costs
Brief: ProKidney Q3 Operating Income USD -53.758 Million
Brief: Prokidney Corp Enters Open Market Sale Agreement With Jefferies
Cell therapy developer ProKidney's Q2 operating loss widens as trial costs rise
Brief: ProKidney Q2 Operating Income USD -48.373 Million
ProKidney Q1 loss widens as R&D spending rises
Brief: ProKidney Q1 Operating Income USD -44.933 Million
Brief: Prokidney Expands Senior Leadership Team With Appointment Of Greg Madison As Chief Commercial Officer
U.S. RESEARCH ROUNDUP-Coca-Cola, Rapid7, Walmart
Brief: Prokidney Corp - Topline Data Readout Of Surrogate Endpoint Expected Q2 2027
Cell therapy firm ProKidney's Q3 net loss narrows
Brief: Prokidney Corp to sell Greensboro property for $19.1 million - SEC filing
Brief: Prokidney Announces Alignment With The FDA On The Accelerated Approval Pathway For Rilparencel
U.S. STOCKS ON THE MOVE-BTCS, BrainStorm Cell, Moderna
U.S. STOCKS ON THE MOVE- Moderna, BrainStorm Cell, General Dynamics
U.S. STOCKS ON THE MOVE-ProKidney, Eton Pharma, Datadog
ProKidney jumps on positive mid-stage data for kidney disease drug
Brief: Prokidney Reports Statistically And Clinically Significant Topline Results For The Phase 2 REGEN-007 Trial
U.S. STOCKS ON THE MOVE-Eve Holding, Magnite, EHang Holdings